Favipiravir is an antiviral drug that has been approved for the treatment of influenza virus infection in Japan and has received some interest in its potential efficacy against filoviruses. Favipiravir has been shown to have broad-spectrum antiviral activity against Marburgviruses (MARV) and Ebolaviruses (EBOV) and the authors also found that it has in vitro and in vivo antiviral activity against Sudan Ebolavirus (SUDV). They found that favipiravir reduces SUDV replication in Vero E6 cells. Subcutaneous administration of the drug, beginning 1-4 days following infection and then continuing for 7 days, was also found to significantly protect SUDV-infected guinea pigs, with a survival rate of 83-100%. Viral RNA replication and infectious virus production were found to be significantly reduced in the blood, spleen, liver, lungs and kidneys of the guinea pigs. In addition, early treatment with low-dose favipiravir and late treatment (5 days following infection) with higher-dose favipiravir also partially protect against SUDV. Therefore favipiravir has antiviral activity against SUDV, suggesting that it could be used during outbreaks.
Read more here